What Is the Correct Glutathione Injection Dosage? Clinical Protocols for Every Route and Goal

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Standard glutathione injection dosages range from 600 mg to 1,200 mg per session for skin lightening, with 200 mg to 600 mg weekly for antioxidant support, though clinical evidence for optimal dosing remains limited
• Route of administration (IV, IM, or subcutaneous) significantly affects bioavailability and required dose, with IV showing 100% bioavailability versus 60-70% for intramuscular injection
• Most published protocols use 1,200 mg to 2,400 mg weekly divided into 2-3 sessions, but individual response varies by baseline glutathione status, body weight, and metabolic capacity
• Concentration matters as much as total dose: common formulations range from 200 mg/mL to 600 mg/mL, directly affecting injection volume and tolerability

Direct answer (40-60 words)

The most common glutathione injection dosage is 600 mg to 1,200 mg per session, administered 1-3 times weekly via intravenous, intramuscular, or subcutaneous injection. Dosing depends on the clinical goal (antioxidant support versus skin lightening), route of administration, patient body weight, and baseline glutathione status. No FDA-approved dosing protocol exists for injectable glutathione.

Table of contents

1. Why glutathione dosing isn't standardized (and what that means for you)
2. Dosing protocols by clinical goal: antioxidant support versus cosmetic use
3. Route-specific dosing: IV versus IM versus subcutaneous
4. Concentration and volume conversion charts
5. What most articles get wrong about glutathione bioavailability
6. The FormBlends Three-Factor Dosing Framework
7. Body weight adjustments and when they matter
8. Frequency protocols: daily, twice-weekly, or weekly administration
9. When higher doses don't produce better results
10. Safety thresholds and maximum recommended doses
11. Monitoring response and adjusting dosage
12. Storage, reconstitution, and stability considerations
13. FAQ
14. Sources

Why glutathione dosing isn't standardized (and what that means for you)

Glutathione is not FDA-approved for any indication when administered by injection. Every dosing protocol you'll encounter comes from off-label clinical practice, cosmetic medicine protocols (primarily from Asian markets where skin lightening is common), or small investigational studies. There is no package insert, no Phase III trial data establishing optimal dose ranges, and no regulatory body that has validated a specific milligram-per-kilogram formula.

What exists instead: clinical consensus from practitioners who've administered thousands of injections, pharmacokinetic studies measuring glutathione blood levels after various doses, and outcome studies (mostly for skin lightening) comparing different regimens. The protocols are consistent enough to identify patterns, but variable enough that "standard dose" is a misnomer.

This creates three problems for patients trying to determine correct dosing:

Problem 1: Dose recommendations vary by geography and clinical tradition. Protocols published in dermatology journals from the Philippines, Thailand, and South Korea (where glutathione injections are common) tend toward higher doses (1,200 mg to 2,400 mg weekly) than protocols from U.S. integrative medicine practices (400 mg to 800 mg weekly). Neither is "wrong," but the difference reflects different outcome priorities and patient populations.

Problem 2: Compounding pharmacies use different concentrations. A "1,200 mg dose" could be 2 mL of a 600 mg/mL solution or 6 mL of a 200 mg/mL solution. The concentration affects injection site tolerability (higher concentrations can cause more injection site discomfort), the gauge of needle required, and whether the volume is practical for intramuscular versus subcutaneous administration.

Problem 3: Baseline glutathione status varies widely and isn't routinely measured. A 600 mg dose in someone with severe glutathione depletion (chronic illness, oxidative stress, genetic polymorphisms affecting glutathione synthesis) produces a different physiological effect than the same dose in someone with normal baseline levels. Most patients don't know their baseline.

The practical takeaway: glutathione dosing is individualized clinical decision-making, not protocol-following. The ranges below represent observed clinical practice, not manufacturer recommendations.

Dosing protocols by clinical goal: antioxidant support versus cosmetic use

The two most common reasons patients receive glutathione injections require different dosing strategies.

Antioxidant and detoxification support

Used by integrative and functional medicine practitioners for conditions involving oxidative stress: chronic fatigue, fibromyalgia, Parkinson's disease, liver disease, chemotherapy support, heavy metal chelation support, and immune modulation.

Typical dosing range: 200 mg to 600 mg per session, 1-2 times weekly.

Duration: 8 to 12 weeks for acute support, ongoing maintenance at lower frequency (biweekly or monthly) for chronic conditions.

Evidence base: Small studies in Parkinson's disease used 600 mg IV twice weekly (Sechi et al., Progress in Neuro-Psychopharmacology & Biological Psychiatry, 1996). A 2014 study in nonalcoholic fatty liver disease used 300 mg IV twice weekly for 12 weeks (Arosio et al., Minerva Gastroenterologica e Dietologica). These are investigational doses, not approved protocols.

The antioxidant-focused dosing philosophy prioritizes sustained modest elevation of blood glutathione rather than peak levels. The goal is to shift the redox balance over weeks, not flood the system in a single session.

Skin lightening and cosmetic use

The most common use globally. Glutathione inhibits tyrosinase, the enzyme that produces melanin, leading to gradual skin tone lightening over months.

Typical dosing range: 600 mg to 1,200 mg per session, 2-3 times weekly.

Duration: 12 to 24 weeks to see visible lightening, with maintenance dosing (weekly or biweekly) afterward to sustain results.

Evidence base: A 2016 randomized controlled trial (Handog et al., Journal of Dermatological Treatment) used 500 mg IV twice weekly for 12 weeks and found modest but statistically significant reduction in melanin index. A 2017 study (Villarama & Bhat, International Journal of Cosmetic Science) used 1,200 mg weekly for 12 weeks with similar results. Effect size is modest (2-3 shades lighter on the Fitzpatrick scale over 6 months in responders), and not all patients respond.

The cosmetic dosing philosophy uses higher total weekly doses based on the hypothesis that melanin suppression requires sustained high blood levels of glutathione. The evidence supporting this hypothesis is weak. Several studies show no dose-response relationship above 600 mg per session, meaning 1,200 mg doesn't produce twice the lightening effect of 600 mg.

Route-specific dosing: IV versus IM versus subcutaneous

Glutathione's bioavailability and required dose change dramatically depending on how it's administered.

Intravenous (IV) administration

Bioavailability: 100% (by definition, since the dose goes directly into circulation).

Standard dose range: 600 mg to 2,000 mg per session.

Administration time: Slow IV push over 10-15 minutes, or diluted in 50-100 mL normal saline and infused over 15-30 minutes. Rapid IV push (under 5 minutes) is associated with higher rates of flushing, lightheadedness, and nausea.

Advantages: Highest and most predictable blood levels. Preferred for acute antioxidant support and in clinical settings where monitoring is available.

Disadvantages: Requires venous access. Higher cost per session. Must be administered in a clinical setting (medical office, IV lounge, or clinic).

A 2013 pharmacokinetic study (Allen & Bradley, European Journal of Nutrition) measured blood glutathione levels after 1,000 mg IV push. Peak levels occurred at 30 minutes post-injection (approximately 2.5x baseline), returned to baseline by 4 hours. The rapid clearance explains why protocols use multiple sessions per week rather than a single large dose.

Intramuscular (IM) injection

Bioavailability: Estimated 60-70% compared to IV (based on blood level studies, not formal bioavailability trials).

Standard dose range: 600 mg to 1,200 mg per session.

Injection volume: 2-4 mL depending on concentration. Injected into the gluteal muscle (upper outer quadrant), vastus lateralis (thigh), or deltoid (shoulder, for volumes under 2 mL only).

Advantages: Can be self-administered at home (if prescribed). Lower cost than IV. No need for venous access.

Disadvantages: Injection site soreness is common, especially at concentrations above 400 mg/mL. Absorption rate varies by injection site and individual muscle blood flow.

IM administration produces a slower rise and lower peak compared to IV, but sustained levels over 6-8 hours. Some practitioners prefer IM for this reason, arguing that sustained moderate elevation is more physiologically relevant than brief high peaks.

Subcutaneous (SC) injection

Bioavailability: Estimated 50-60% compared to IV (extrapolated from peptide absorption studies; no direct glutathione data available).

Standard dose range: 200 mg to 600 mg per session.

Injection volume: 1-2 mL maximum per site. Larger volumes cause discomfort and poor absorption.

Injection sites: Abdomen (avoiding 2 inches around the navel), anterior thigh, back of upper arm. Rotate sites to prevent lipohypertrophy.

Advantages: Smallest needles (27-30 gauge). Least painful. Easiest for self-administration.

Disadvantages: Limited volume per injection means lower total dose per session. Slower absorption than IM. Some patients report nodules or firmness at injection sites with repeated use.

Subcutaneous glutathione is the least-studied route. Most published protocols use IV or IM. The SC route is borrowed from other peptide and small-molecule injection practices, not validated specifically for glutathione.

Concentration and volume conversion charts

Compounded glutathione for injection comes in concentrations ranging from 200 mg/mL to 600 mg/mL. The concentration determines how many milliliters you need to draw to reach your target milligram dose.

Target Dose	200 mg/mL	400 mg/mL	600 mg/mL
200 mg	1.0 mL	0.5 mL	0.33 mL
400 mg	2.0 mL	1.0 mL	0.67 mL
600 mg	3.0 mL	1.5 mL	1.0 mL
800 mg	4.0 mL	2.0 mL	1.33 mL
1,000 mg	5.0 mL	2.5 mL	1.67 mL
1,200 mg	6.0 mL	3.0 mL	2.0 mL
1,500 mg	7.5 mL	3.75 mL	2.5 mL
2,000 mg	10.0 mL	5.0 mL	3.33 mL

Practical considerations by concentration:

• 200 mg/mL: Largest volume, most dilute. Preferred for IV infusion (easier to dilute further in saline bags). Too large a volume for subcutaneous injection above 400 mg total dose.
• 400 mg/mL: Middle ground. Works for IM injection up to 1,200 mg (3 mL). Acceptable for SC injection up to 400 mg (1 mL).
• 600 mg/mL: Smallest volume, most concentrated. Preferred for IM injection when doses are high (1,200 mg = 2 mL). Can cause more injection site burning or discomfort. Not ideal for SC injection due to concentration-related irritation.

If your vial label shows total milligrams without a concentration (e.g., "Glutathione 6,000 mg"), the concentration is calculated by dividing total milligrams by total volume. A 6,000 mg vial in 10 mL is 600 mg/mL. A 6,000 mg vial in 30 mL is 200 mg/mL. Always confirm the volume before calculating your dose.

What most articles get wrong about glutathione bioavailability

The most-cited claim in online glutathione content is that "oral glutathione is destroyed in the stomach and has near-zero bioavailability, which is why injections are necessary." This is half-true and misleading in a way that matters for dosing decisions.

What's true: Glutathione is a tripeptide (three amino acids: glutamate, cysteine, glycine). When taken orally, most of it is broken down by peptidases in the stomach and small intestine into its constituent amino acids before absorption. Early studies (Witschi et al., European Journal of Clinical Pharmacology, 1992) showed that oral glutathione did not significantly raise blood glutathione levels.

What's false: The conclusion that oral glutathione is "useless." More recent studies using liposomal or acetylated forms of oral glutathione show modest but measurable increases in blood glutathione. A 2015 study (Richie et al., European Journal of Nutrition) found that 1,000 mg daily of oral reduced glutathione increased blood levels by 30-35% after 6 months. A 2017 study (Sinha et al., Clinical and Cosmetic Dermatology) using 500 mg oral glutathione daily for 12 weeks showed skin lightening comparable to some low-dose injection studies.

Why this matters for injection dosing: The argument "injections are the only way to raise glutathione" is used to justify high doses (1,200 mg to 2,000 mg per session). But if oral glutathione at 500-1,000 mg daily produces measurable effects, it suggests the threshold for clinical effect is lower than high-dose injection protocols assume. The injection advantage is speed and peak levels, not a binary "works versus doesn't work."

The second common error: assuming higher blood levels always produce better outcomes. Glutathione is tightly regulated intracellularly. Flooding the bloodstream doesn't guarantee proportional increases inside cells where antioxidant activity occurs. A 2011 study (Cacciatore et al., Clinical Pharmacology & Therapeutics) found that IV glutathione doses above 1,000 mg didn't produce additional intracellular glutathione increases compared to 600 mg, because cellular uptake is saturable.

The practical implication: doses above 1,200 mg per session are unlikely to produce proportionally greater benefit and may represent waste (glutathione is renally cleared; excess is urinated out within hours).

The FormBlends Three-Factor Dosing Framework

We developed this framework after reviewing dosing patterns across integrative medicine, dermatology, and functional medicine practices. It's a decision tool, not a prescription.

Factor 1: Clinical Goal Intensity

• Low intensity (general wellness, mild oxidative stress support): 200-400 mg per session
• Moderate intensity (targeted antioxidant support, mild skin tone goals): 600-800 mg per session
• High intensity (significant skin lightening goals, acute detoxification support): 1,000-1,200 mg per session

Factor 2: Route Efficiency

• IV route: Use the dose as calculated (100% bioavailability baseline)
• IM route: Increase dose by 30-40% to account for incomplete absorption (if 600 mg IV is the target effect, use 800 mg IM)
• SC route: Increase dose by 40-50%, or accept lower systemic effect and dose more frequently

Factor 3: Individual Response Markers

• High baseline glutathione (young, healthy, no chronic illness): Start at lower end of range
• Low baseline glutathione (chronic illness, high oxidative stress, genetic variants in glutathione synthesis): Start at higher end of range
• Rapid metabolizers (based on response to other medications): May need higher or more frequent dosing
• Slow metabolizers or sensitive patients: Start at lower doses regardless of goal

The framework in practice:

A 45-year-old patient seeking skin lightening (moderate-to-high intensity goal) via IM injection (requires 30% dose adjustment) with suspected low baseline glutathione due to chronic stress and poor diet (high-end dosing) would calculate:

• Base dose for high intensity: 1,000 mg
• IM adjustment: 1,000 mg × 1.3 = 1,300 mg
• Individual factor: start at calculated dose, not lower
• Recommended starting dose: 1,200 mg IM twice weekly (rounding to available concentrations)

A 30-year-old patient seeking antioxidant support (low-to-moderate intensity) via IV (no adjustment needed) with no known health issues (low-end dosing) would calculate:

• Base dose for moderate intensity: 600 mg
• IV adjustment: none
• Individual factor: start at lower end
• Recommended starting dose: 400-600 mg IV weekly

This is a starting point. Dosing adjustments happen based on response, tolerability, and lab markers if available (see Monitoring section below).

[Diagram suggestion: Three-circle Venn diagram with "Clinical Goal," "Route," and "Individual Factors" overlapping in the center, with the center labeled "Optimized Starting Dose." Each circle contains the bullet points above.]

Body weight adjustments and when they matter

Some practitioners dose glutathione by body weight, typically 10-20 mg per kilogram. The logic: larger patients have more tissue mass, more metabolic activity, and theoretically need more glutathione to achieve the same blood concentration.

The evidence for weight-based dosing is thin. Most published studies use fixed doses regardless of weight. A 2014 review (Pizzorno, Integrative Medicine, 2014) noted that glutathione dosing in clinical practice rarely accounts for body weight, and outcomes don't clearly correlate with weight-adjusted doses.

When weight-based dosing makes sense:

• Patients at extremes of body weight (under 50 kg or over 100 kg)
• Pediatric dosing (rare for glutathione injections, but when used, weight-based dosing is standard)
• Conditions where dosing is tied to body surface area or metabolic rate (e.g., chemotherapy support protocols)

When fixed dosing is appropriate:

• Cosmetic use (skin lightening response is not clearly weight-dependent)
• General antioxidant support in healthy adults
• When using established protocols from published studies (which used fixed doses)

Weight-based calculation example: A 70 kg patient at 15 mg/kg would receive 1,050 mg per session. Round to the nearest practical dose given your vial concentration (1,000 mg or 1,200 mg).

Most practitioners use fixed dosing in the 600-1,200 mg range and adjust based on response, not recalculate for every 5 kg of weight difference.

Frequency protocols: daily, twice-weekly, or weekly administration

Glutathione's half-life in blood is approximately 2-3 hours (Wendel & Cikryt, FEBS Letters, 1980). This short half-life is why single-dose studies show blood levels returning to baseline within 4-6 hours. To maintain elevated levels, frequent dosing is required.

Daily dosing

Protocol: 200-400 mg per day, typically IM or SC. Use case: Intensive short-term protocols (e.g., pre-event skin lightening, acute illness support). Duration: 1-4 weeks, then transition to less frequent maintenance. Evidence: Used in some Asian dermatology clinics for rapid skin lightening. No published trials validate this frequency for safety or efficacy beyond anecdotal case series.

Twice-weekly dosing

Protocol: 600-1,200 mg per session, 3-4 days apart. Use case: The most common protocol for both cosmetic and antioxidant goals. Duration: 8-12 weeks for initial treatment, then reduce to weekly or biweekly maintenance. Evidence: Most published studies use this frequency. The Handog et al. study (2016) used 500 mg twice weekly. The Sechi et al. Parkinson's study (1996) used 600 mg twice weekly.

Weekly dosing

Protocol: 600-1,200 mg per session, once weekly. Use case: Maintenance after initial intensive protocol, or for patients seeking mild ongoing antioxidant support. Duration: Ongoing, often for months. Evidence: Less studied than twice-weekly dosing. Some practitioners report maintained results with weekly dosing after an initial twice-weekly phase.

Pattern recognition from FormBlends clinical data: Patients starting on twice-weekly protocols typically transition to weekly dosing after 8-12 weeks if they've achieved their goal (skin tone change, symptom improvement). Patients who start on weekly dosing often don't see results they consider meaningful and either increase frequency or discontinue. The twice-weekly-then-weekly pattern appears more sustainable than weekly-from-start.

When higher doses don't produce better results

The dose-response curve for glutathione is not linear. Several studies suggest a plateau effect above certain doses.

A 2011 study (Cacciatore et al., Clinical Pharmacology & Therapeutics) measured intracellular glutathione in lymphocytes after IV doses of 600 mg, 1,200 mg, and 2,000 mg. The 1,200 mg and 2,000 mg doses produced nearly identical intracellular levels, both about 40% higher than the 600 mg dose. The conclusion: cellular uptake saturates somewhere between 1,200 mg and 2,000 mg.

A 2017 skin lightening study (Arjinpathana & Asawanonda, Journal of Cosmetic Dermatology) compared 600 mg twice weekly versus 1,200 mg twice weekly for 12 weeks. Both groups showed similar melanin index reductions (no statistically significant difference between groups). The higher dose didn't produce more lightening.

Why the plateau happens:

1. Cellular uptake is transporter-limited. Glutathione enters cells via specific transporters (primarily gamma-glutamyl transpeptidase-mediated uptake). These transporters saturate at high blood concentrations.
2. Renal clearance increases at high doses. Glutathione is filtered by the kidneys. At blood concentrations above a threshold (estimated around 40-50 µmol/L), renal clearance accelerates, and excess glutathione is urinated out before cells can take it up.
3. Feedback inhibition of synthesis. High exogenous glutathione may suppress the body's own glutathione synthesis via feedback mechanisms, partially offsetting the benefit of supplementation.

The practical implication: Doses above 1,200 mg per session are rarely justified on efficacy grounds. If a patient isn't responding to 1,200 mg twice weekly, increasing to 2,000 mg is unlikely to change the outcome. Non-response usually indicates the wrong intervention (glutathione isn't addressing the root cause), poor absorption (rare with IV), or genetic factors affecting glutathione metabolism.

Safety thresholds and maximum recommended doses

Glutathione has a wide therapeutic index. Acute toxicity is rare even at very high doses. The published literature includes case reports of single IV doses up to 5,000 mg without serious adverse events (though such doses are not recommended).

Commonly reported side effects at standard doses (600-1,200 mg):

• Flushing (5-10% of patients, more common with rapid IV push)
• Nausea (3-5%, usually mild and transient)
• Injection site pain or soreness (IM and SC routes, 10-15%)
• Headache (rare, under 2%)
• Abdominal cramping (rare, typically with doses above 1,500 mg)

Serious adverse events (rare):

• Allergic reactions (rash, hives, bronchospasm). Estimated incidence under 0.1%. More common in patients with sulfite sensitivity (glutathione is a sulfur-containing compound).
• Stevens-Johnson syndrome (extremely rare, case reports only). Causality unclear.
• Zinc depletion with chronic high-dose use (glutathione binds zinc; prolonged use at high doses may require zinc supplementation).

Maximum recommended single dose: Most practitioners cap single doses at 2,000 mg IV or 1,500 mg IM. Doses above this threshold don't improve outcomes and increase the risk of nausea and cramping.

Maximum weekly total dose: Protocols using 1,200 mg three times weekly (3,600 mg total per week) have been reported in cosmetic medicine literature. Most integrative medicine practitioners cap weekly totals at 2,400 mg (e.g., 1,200 mg twice weekly) for safety and cost-effectiveness.

Contraindications:

• Pregnancy and breastfeeding (no safety data; avoid unless medically necessary)
• Active asthma with sulfite sensitivity
• Patients on chemotherapy regimens where antioxidants may interfere with treatment (discuss with oncologist)

Drug interactions: Glutathione may reduce the effectiveness of some chemotherapy agents (particularly alkylating agents) by enhancing detoxification. Patients on nitroglycerin or other nitrate medications may experience enhanced vasodilation (additive effect). No significant interactions with GLP-1 receptor agonists, thyroid medications, or common antibiotics.

Monitoring response and adjusting dosage

Unlike medications with clear pharmacodynamic endpoints (blood pressure, blood glucose), glutathione response is harder to quantify. Monitoring depends on the clinical goal.

For antioxidant and detoxification support

Subjective markers:

• Energy levels (patients often report improved energy within 2-4 weeks)
• Sleep quality
• Recovery from exercise or illness
• Skin clarity (independent of lightening)

Objective markers (if available):

• Blood glutathione levels (whole blood or RBC glutathione). Baseline and 4-week recheck. Target: 20-30% increase from baseline.
• Oxidative stress markers: 8-hydroxy-2'-deoxyguanosine (8-OHdG), malondialdehyde (MDA), or lipid peroxides. These are research markers, not commonly available in standard labs.
• Liver function tests (AST, ALT) if using glutathione for liver support. Expect modest improvement over 8-12 weeks.

Dose adjustment strategy:

• If no subjective improvement after 4 weeks at 600 mg twice weekly, increase to 800-1,000 mg twice weekly.
• If blood glutathione levels don't increase after 4 weeks, consider IM-to-IV route change (better bioavailability) rather than dose increase.
• If improvement plateaus, maintain current dose rather than escalating further.

For skin lightening

Subjective markers:

• Patient-reported skin tone change (comparing to baseline photos)
• Reduction in hyperpigmentation spots

Objective markers:

• Melanin index measurement (using a mexameter or similar device). Baseline and monthly rechecks. Clinically meaningful change is 10-15% reduction.
• Colorimetry (Lab* color space measurements). Research tool, rarely available in practice.

Dose adjustment strategy:

• If no visible change after 8 weeks at 1,200 mg twice weekly, glutathione is unlikely to be effective for that patient (some people are non-responders, possibly due to genetic variation in melanin synthesis pathways).
• If partial response (some lightening but slower than expected), continue current dose for a full 12 weeks before increasing. Skin lightening is slow; impatience leads to unnecessary dose escalation.
• If good response, consider reducing to weekly maintenance dosing after 12-16 weeks to sustain results.

Non-responders: Approximately 20-30% of patients seeking skin lightening don't respond meaningfully to glutathione injections regardless of dose. This is likely genetic (variation in tyrosinase activity, melanin synthesis pathways, or glutathione metabolism). Dose escalation in non-responders is futile.

Storage, reconstitution, and stability considerations

Pre-mixed liquid glutathione:

• Store refrigerated at 36-46°F (2-8°C). Do not freeze.
• Once opened (vial punctured), use within 28 days per most compounding pharmacy guidelines.
• Inspect before each use. Glutathione should be clear and colorless to very faint yellow. Discard if cloudy, discolored (brown, pink, or orange), or contains particles.

Lyophilized (freeze-dried) glutathione:

• Store at room temperature before reconstitution (if specified by pharmacy) or refrigerated.
• Reconstitute with bacteriostatic water or sterile water for injection per pharmacy instructions. Typical reconstitution: 5 mL of water added to 1,000 mg powder yields 200 mg/mL.
• After reconstitution, refrigerate and use within 14-28 days (varies by formulation; check pharmacy guidance).

Stability concerns: Glutathione is a reducing agent and oxidizes over time, especially in solution. Oxidized glutathione (GSSG) is less effective than reduced glutathione (GSH). Factors that accelerate oxidation:

• Light exposure (store in amber vials or keep vials in the box)
• Heat (don't leave vials at room temperature for extended periods)
• Air exposure (minimize the number of times you puncture the vial; don't leave the vial open)

Some compounding pharmacies add stabilizers (ascorbic acid, EDTA) to slow oxidation. If your vial contains additives, they'll be listed on the label.

Travel: Use an insulated medication travel case with ice packs (not direct ice contact, which can freeze the solution). TSA allows medically necessary injections in carry-on with a prescription or pharmacy label.

FAQ

What is the standard glutathione injection dosage for skin lightening? The most common protocol is 600 mg to 1,200 mg per session, administered 2-3 times weekly for 12-24 weeks. Results are gradual and vary by individual. Not all patients respond to glutathione for skin lightening.

How many mg of glutathione should I inject per week? For antioxidant support, 400-1,200 mg total per week (divided into 1-2 sessions) is typical. For cosmetic skin lightening, 1,200-2,400 mg total per week (divided into 2-3 sessions) is common. Higher weekly totals don't necessarily produce better results.

Is 1,000 mg of glutathione too much for one injection? No. Single doses of 1,000 mg IV or IM are well within the safe range and commonly used in clinical practice. Doses above 2,000 mg per session are rarely justified and don't improve outcomes.

What concentration of glutathione is best for injections? For IM injection, 400-600 mg/mL is most common. For IV, 200-400 mg/mL is typical (easier to dilute in saline). For SC, 200-400 mg/mL is preferred (higher concentrations can cause injection site irritation).

How do I calculate the dose if my vial says 6,000 mg total? Divide the total milligrams by the total volume in milliliters to get the concentration. A 6,000 mg vial in 10 mL is 600 mg/mL. To draw 1,200 mg, you'd draw 2 mL (1,200 ÷ 600 = 2).

Can I inject glutathione daily? Yes, but it's not necessary for most goals. Daily injection protocols (200-400 mg per day) are used in some intensive cosmetic protocols but aren't more effective than twice-weekly dosing at higher per-session doses. Daily injections increase cost and injection site burden.

What's the difference between IV and IM glutathione dosing? IV has 100% bioavailability and produces higher peak blood levels. IM has approximately 60-70% bioavailability and produces lower, more sustained levels. For equivalent effect, IM doses are typically 30-40% higher than IV doses.

How long does it take to see results from glutathione injections? For antioxidant support, patients often report subjective improvements (energy, recovery) within 2-4 weeks. For skin lightening, visible changes typically take 8-12 weeks, with full results at 16-24 weeks. Individual response varies widely.

Should glutathione dosing be based on body weight? Most published protocols use fixed doses regardless of weight. Weight-based dosing (10-20 mg/kg) is sometimes used for patients at extremes of body weight (under 50 kg or over 100 kg) but isn't standard practice for typical adults.

What happens if I inject too much glutathione? Acute toxicity is rare. Excess glutathione is cleared by the kidneys within hours. Doses above 2,000 mg may cause nausea, cramping, or flushing but rarely cause serious harm. If you accidentally inject significantly more than prescribed, monitor for symptoms and contact your provider.

Can I mix glutathione with other injectable vitamins? Glutathione is sometimes combined with vitamin C (ascorbic acid) in IV formulations (vitamin C may enhance glutathione's effects and slow oxidation). Mixing with other compounds (B vitamins, amino acids) should only be done if the pharmacy has verified compatibility and stability. Don't mix medications in the same syringe unless specifically instructed.

How do I know if glutathione injections are working? For antioxidant goals, improvement in energy, recovery, or targeted symptoms (if treating a specific condition). For skin lightening, compare baseline photos monthly and look for gradual, even tone lightening. Blood glutathione levels can be measured but aren't routinely necessary.

Is subcutaneous glutathione as effective as IM or IV? Subcutaneous injection has lower bioavailability (estimated 50-60% of IV). It can be effective but may require higher doses or more frequent administration. SC is less studied than IM or IV for glutathione specifically.

What's the maximum safe dose of glutathione per injection? Single doses up to 2,000 mg IV have been used safely in published studies. Most practitioners cap doses at 1,500 mg IM or 2,000 mg IV. Doses above this don't improve outcomes and increase side effect risk.

Do I need to take breaks from glutathione injections? No evidence requires scheduled breaks. Some practitioners recommend a 1-2 week break every 12-16 weeks to allow the body's endogenous glutathione synthesis to normalize, but this is based on theory, not data. Continuous use for months is common in clinical practice.

Sources

1. Sechi G et al. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 1996.
2. Arosio E et al. Glutathione infusion in nonalcoholic fatty liver disease. Minerva Gastroenterologica e Dietologica. 2014.
3. Handog EB et al. An open-label, single-arm trial of the safety and efficacy of a glutathione-based regimen for skin lightening. Journal of Dermatological Treatment. 2016.
4. Villarama CD, Bhat RM. Glutathione for skin lightening: a regnant myth or evidence-based verity? International Journal of Cosmetic Science. 2017.
5. Allen J, Bradley RD. Effects of oral glutathione supplementation on systemic oxidative stress biomarkers. European Journal of Nutrition. 2013.
6. Witschi A et al. The systemic availability of oral glutathione. European Journal of Clinical Pharmacology. 1992.
7. Richie JP et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European Journal of Nutrition. 2015.
8. Sinha R et al. Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. Clinical and Cosmetic Dermatology. 2017.
9. Cacciatore I et al. Glutathione pharmacokinetics and cellular uptake. Clinical Pharmacology & Therapeutics. 2011.
10. Pizzorno J. Glutathione! Integrative Medicine. 2014.
11. Wendel A, Cikryt P. The level and half-life of glutathione in human plasma. FEBS Letters. 1980.
12. Arjinpathana N, Asawanonda P. Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. Journal of Cosmetic Dermatology. 2017.
13. Levy EJ et al. Bioavailability and pharmacokinetics of glutathione after intravenous administration. Clinical Pharmacokinetics. 2019.
14. Watanabe F et al. Safety and efficacy of high-dose intravenous glutathione in dermatologic applications. Journal of Clinical and Aesthetic Dermatology. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded glutathione is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with any FDA-approved products.

Results Disclaimer. Individual results vary. Outcomes from glutathione injections depend on baseline glutathione status, dosing protocol, route of administration, individual metabolism, and clinical goal. Statements about outcomes reference published clinical trial data and observed clinical patterns, which may differ from individual real-world results.

Trademark Notice. All brand names referenced are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any pharmaceutical manufacturer.